@Article{or.2024.046885,
AUTHOR = {CONSTANTINE N. LOGOTHETIS, NATHAN P. HORVAT, TONY KURIAN, CELESTE BELLO, JULIO CHAVEZ, LEIDY ISENALUMHE, BIJAL SHAH, LUBOMIR SOKOL, HAYDER SAEED, JAVIER PINILLA, SAMEH GABALLA},
TITLE = {Bendamustine and rituximab as frontline therapy in extranodal marginal zone lymphoma: a single-institution experience},
JOURNAL = {Oncology Research},
VOLUME = {32},
YEAR = {2024},
NUMBER = {6},
PAGES = {1031--1036},
URL = {http://www.techscience.com/or/v32n6/56595},
ISSN = {1555-3906},
ABSTRACT = {Extranodal marginal zone lymphoma (EMZL) encompasses 70% of cases of marginal zone lymphoma. Frontline bendamustine and rituximab (BR) were derived from trials involving other indolent non-Hodgkin’s lymphomas. Only one trial has evaluated frontline BR prospectively in EMZL. This retrospective study reports outcomes among EMZL patients receiving frontline BR. Twenty-five patients were included with a median age of 69 years (40–81). Five (20.0%) patients had stage I/II disease, and 20 (80.0%) had stage III/IV disease. The median number of cycles was 6.0 (3.0–6.0). Maintenance rituximab was administered to 10 (41.7%) individuals. Overall response rate (ORR) was 100.0% (60.0% complete response, 40.0% partial response). Medians of overall survival and progression-free survival were not reached. The estimated 2-year progression-free survival was 85.2% and overall survival was 100.0%. Four (16.6%) patients had infections related to treatment; 3 (12.0%) transformed to diffuse large B-cell lymphoma; 5 (20.8%) had a relapse or progression of EMZL; and 3 (12.0%) died unrelated to BR. BR is an efficacious and well-tolerated front-line regimen for EMZL with response data consistent with existing literature.},
DOI = {10.32604/or.2024.046885}
}